Skip to main content
Edward Bastyr, MD, Endocrinology, Indianapolis, IN

EdwardJBastyrMD

Endocrinology Indianapolis, IN

Diabetes, Lipid Metabolism

Consultant, Diabetes Drug Development, Associate Professor (voluntary), Indiana University School of Medicine

Dr. Bastyr is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Bastyr's full profile

Already have an account?

  • Office

    720 Eskenazi Ave
    # Univ
    Indianapolis, IN 46202
    Phone+1 317-880-5045
    Fax+1 317-880-0414

Summary

  • Dr. Edward Bastyr is an endocrinologist in Indianapolis, IN and is affiliated with Eskenazi Health. He received his medical degree from Universidad de Navarra Faculty of Medicine and has been in practice 34 years. He also speaks multiple languages, including Spanish. He specializes in diabetes and lipid metabolism and is experienced clinical researcher in diabetes mellitus and obesity and obesity-related disorders.

Education & Training

  • University of Michigan
    University of MichiganFellowship, Endocrinology, Diabetes, and Metabolism, 1985 - 1988
  • UPMC Medical Education/Mercy
    UPMC Medical Education/MercyResidency, Internal Medicine, 1983 - 1985
  • UPMC Medical Education/Mercy
    UPMC Medical Education/MercyInternship, Internal Medicine, 1982 - 1983
  • Universidad de Navarra Faculty of Medicine
    Universidad de Navarra Faculty of MedicineClass of 1982
  • Wagner College
    Wagner CollegeMS, Microbiology, 1977 - 1978
  • University of Chicago
    University of ChicagoMS, Biochemistry, 1976 - 1977
  • Columbia College, Columbia University
    Columbia College, Columbia UniversityAB, Biochemistry, 1972 - 1976

Certifications & Licensure

  • IN State Medical License
    IN State Medical License 1995 - 2025
  • PA State Medical License
    PA State Medical License 1983 - 2024
  • TX State Medical License
    TX State Medical License 1989 - 1996
  • MI State Medical License
    MI State Medical License 1985 - 1992
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

  • President's Recognition Award For Outstanding Scientific Achievement (1% Award) Lilly Research Laboratories, 2002, 2009, 2014
  • Lincoln Fund Fellow Rockefeller University, 1975
  • Honorarium University of Pittsburgh, 1973

Publications & Presentations

PubMed

Journal Articles

  • The PNPLA3 I148M Variant is Associated with Transaminase Elevations in Type 2 Diabetes (T2D) Patients Treated with Basal Insulin Peglispro (BIL)  
    Pillai S, Duvvuru S, Bhatnagar P, Foster W, Farmen M, Shankar S, Harris C, Bastyr EJ III, Hoogwerf B, and A Haupt, The Pharmacogenomics Journal, 1/1/2016
  • Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes  
    Cusi K, Sanyal AJ, Zhang S, Hoogwerf BJ, Chang AM, Jacober SJ, Bue-Valleskey JM,Higdon AN, Bastyr EJ III, Haupt A and Hartman ML, Diabetes, Obesity and Metabolism, 1/1/2016
  • Reduced Nocturnal Hypoglycemia with Basal Insulin Peglispro Compared to Insulin Glargine (GL): Pooled Analyses of 5 Randomized Controlled Trials  
    Rosenstock J, Marre M, Qu Y, Zhang S, Bastyr EJ III, Prince MJ, Chang AM, Diabetes, Obesity and Metabolism, 1/1/2016
  • Join now to see all

Abstracts/Posters

  • Greater HbA1c Reduction with Basal Insulin Peglispro (BIL) v Insulin Glargine (GL) in an Open-label, Randomized Study in T1D Patients (pts): IMAGINE 1
    Garg SK, Jinnouchi H, Dreyer M, Mou J, Hartman ML, Rosilio M, Bastyr EJ III for the IMAGINE 1 Study Group, American Diabetes Association National Meeting; Diabetes, Boston, MA, 1/1/2015
  • Superior HbA1c Reduction with Basal Insulin Peglispro (BIL) vs Insulin Glargine (GL) and Preprandial Insulin Lispro in a Double-blind Study in Patients (pts) with Type...
    Blevins T, Pieber TR, Vega GC, Zhang S, Bastyr EJ III, Chang AM, American Diabetes Association National Meeting; Diabetes, Boston, MA, 1/1/2015
  • Superior Reduction of HbA1c in a Double-blind, Randomized Study of Basal Insulin Peglispro (BIL) v Insulin Glargine (GL) in Patients (pts) with T1D: IMAGINE 3
    Bergenstal RM, Lunt H, Franek E, Travert F, Mou J, Hartman ML, Rosilio M, Bastyr EJ III for the IMAGINE 3 Study Group, American Diabetes Association National Meeting; Diabetes, Boston, MA, 1/1/2015
  • Join now to see all

Lectures

  • Electronic Data Capture in Insulin Management for Patients (pts) with Type 1 (T1DM) and Type 2 (T2DM) Diabetes Mellitus in Global Clinical Trials 
    Indianapolis, IN - 6/14/2014
  • LY2605541, A Novel Long-Acting Basal Insulin Analog 
    Colegio de Medicos de España, Madrid, Spain - 1/1/2012
  • Postprandial Blood Glucose is a Better Predictor of Overall Metabolic Control in Diabetes Mellitus 
    Norfolk, VA - 1/1/2000
  • Join now to see all

Professional Memberships

Other Languages

  • Spanish